992 related articles for article (PubMed ID: 18927288)
21. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
[TBL] [Abstract][Full Text] [Related]
22. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers.
Inoue M; Senju S; Hirata S; Ikuta Y; Hayashida Y; Irie A; Harao M; Imai K; Tomita Y; Tsunoda T; Furukawa Y; Ito T; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2010 Sep; 127(6):1393-403. PubMed ID: 20063317
[TBL] [Abstract][Full Text] [Related]
23. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
[TBL] [Abstract][Full Text] [Related]
24. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
[TBL] [Abstract][Full Text] [Related]
25. Targeting p53 for adoptive T-cell immunotherapy.
McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
[TBL] [Abstract][Full Text] [Related]
26. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL.
Harao M; Hirata S; Irie A; Senju S; Nakatsura T; Komori H; Ikuta Y; Yokomine K; Imai K; Inoue M; Harada K; Mori T; Tsunoda T; Nakatsuru S; Daigo Y; Nomori H; Nakamura Y; Baba H; Nishimura Y
Int J Cancer; 2008 Dec; 123(11):2616-25. PubMed ID: 18770861
[TBL] [Abstract][Full Text] [Related]
27. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
28. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
[TBL] [Abstract][Full Text] [Related]
29. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
[TBL] [Abstract][Full Text] [Related]
30. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
32. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
33. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones.
Perez SA; Sotiropoulou PA; Sotiriadou NN; Mamalaki A; Gritzapis AD; Echner H; Voelter W; Pawelec G; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2002 Jan; 50(11):615-24. PubMed ID: 11807625
[TBL] [Abstract][Full Text] [Related]
34. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
[TBL] [Abstract][Full Text] [Related]
35. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
Makita M; Hiraki A; Azuma T; Tsuboi A; Oka Y; Sugiyama H; Fujita S; Tanimoto M; Harada M; Yasukawa M
Clin Cancer Res; 2002 Aug; 8(8):2626-31. PubMed ID: 12171894
[TBL] [Abstract][Full Text] [Related]
36. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
[TBL] [Abstract][Full Text] [Related]
37. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
[TBL] [Abstract][Full Text] [Related]
38. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
39. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
40. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
